{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SBR",
    "query": {
      "intervention": "SBR"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SBR&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-01T22:04:47.902Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07708584",
      "title": "Brostrom Chronic Lateral Ankle Instability Repairs Augmented With BioBrace®",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lateral Ankle Instability",
        "Chronic Lateral Ankle Instability",
        "Brostrom Procedure",
        "ATFL",
        "Anterior Talofibular Ligament",
        "Ankle",
        "Bioinductive Implant"
      ],
      "interventions": [
        {
          "name": "Standard Brostrom Repair",
          "type": "PROCEDURE"
        },
        {
          "name": "Brostrom repair with augmentation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 75,
      "start_date": "2026-09",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-01T22:04:47.902Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07708584"
    },
    {
      "nct_id": "NCT01474395",
      "title": "N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "D-serine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Sensory Based remediation paradigm",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Nathan Kline Institute for Psychiatric Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 16,
      "start_date": "2012-03",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2012-10-25",
      "last_synced_at": "2026-09-01T22:04:47.902Z",
      "location_count": 1,
      "location_summary": "Orangeburg, New York",
      "locations": [
        {
          "city": "Orangeburg",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01474395"
    },
    {
      "nct_id": "NCT05729568",
      "title": "A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Teropavimab",
          "type": "DRUG"
        },
        {
          "name": "Zinlirvimab",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir Tablet",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir Injection",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 83,
      "start_date": "2023-05-15",
      "completion_date": "2030-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-09-01T22:04:47.902Z",
      "location_count": 29,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 25 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05729568"
    },
    {
      "nct_id": "NCT01252940",
      "title": "Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "FTC/RPV/TDF",
          "type": "DRUG"
        },
        {
          "name": "PI",
          "type": "DRUG"
        },
        {
          "name": "RTV",
          "type": "DRUG"
        },
        {
          "name": "NRTIs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 482,
      "start_date": "2010-11",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2015-12-04",
      "last_synced_at": "2026-09-01T22:04:47.902Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01252940"
    },
    {
      "nct_id": "NCT07683000",
      "title": "Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Lenacapavir",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir Tablet",
          "type": "DRUG"
        },
        {
          "name": "Teropavimab",
          "type": "DRUG"
        },
        {
          "name": "Zinlirvimab",
          "type": "DRUG"
        },
        {
          "name": "SBR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2026-07-14",
      "completion_date": "2033-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-01T22:04:47.902Z",
      "location_count": 2,
      "location_summary": "Berkeley, Michigan • Annandale, Virginia",
      "locations": [
        {
          "city": "Berkeley",
          "state": "Michigan"
        },
        {
          "city": "Annandale",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07683000"
    },
    {
      "nct_id": "NCT02038959",
      "title": "Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their Homes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Virtual Visits",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2014-03",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2017-01-27",
      "last_synced_at": "2026-09-01T22:04:47.902Z",
      "location_count": 20,
      "location_summary": "San Francisco, California • Sunnyvale, California • Gainsville, Florida + 16 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Gainsville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02038959"
    },
    {
      "nct_id": "NCT01815736",
      "title": "Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "E/C/F/TDF",
          "type": "DRUG"
        },
        {
          "name": "EFV/FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "RTV",
          "type": "DRUG"
        },
        {
          "name": "ATV",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "COBI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1443,
      "start_date": "2013-03-27",
      "completion_date": "2020-04-01",
      "has_results": true,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-09-01T22:04:47.902Z",
      "location_count": 91,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01815736"
    },
    {
      "nct_id": "NCT03631732",
      "title": "Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "NRTIs",
          "type": "DRUG"
        },
        {
          "name": "Third Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 496,
      "start_date": "2018-08-28",
      "completion_date": "2020-08-19",
      "has_results": true,
      "last_update_posted_date": "2021-09-05",
      "last_synced_at": "2026-09-01T22:04:47.902Z",
      "location_count": 82,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03631732"
    },
    {
      "nct_id": "NCT05502341",
      "title": "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Bictegravir",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir",
          "type": "DRUG"
        },
        {
          "name": "BIC/LEN FDC",
          "type": "DRUG"
        },
        {
          "name": "Stable Baseline Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 689,
      "start_date": "2022-08-16",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-01T22:04:47.902Z",
      "location_count": 40,
      "location_summary": "Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05502341"
    },
    {
      "nct_id": "NCT02603107",
      "title": "Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "RTV",
          "type": "DRUG"
        },
        {
          "name": "ATV",
          "type": "DRUG"
        },
        {
          "name": "DRV",
          "type": "DRUG"
        },
        {
          "name": "COBI",
          "type": "DRUG"
        },
        {
          "name": "ATV/co",
          "type": "DRUG"
        },
        {
          "name": "DRV/co",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "ABC/3TC",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 578,
      "start_date": "2015-11-20",
      "completion_date": "2019-12-23",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-09-01T22:04:47.902Z",
      "location_count": 63,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603107"
    }
  ]
}